natgillin/translations-raw huggingface dataset:
Complaints of injection site reactions (injection site reaction, injection site pain) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.
O pritožbah zaradi reakcij na mestu injiciranja (bolečina na mestu injiciranja, reakcija na mestu injiciranja) in kožnih reakcij (izpuščaj, urtikarija) so poročali relativno bolj pogosto pri otrocih in mladostnikih, starih 18 let ali manj, kot pri odraslih bolnikih.
Complaints of injection site reactions (injection site reaction, injection site pain) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.
O pritožbah zaradi reakcij na mestu injiciranja (reakcija na mestu injiciranja, bolečina na mestu injiciranja ) in kožnih reakcij (izpuščaj, urtikarija) so poročali relativno bolj pogosto pri otrocih in mladostnikih, starih 18 let ali manj, kot pri odraslih bolnikih.
Complete
popoln
Complete (CCyR)
Celovit (CCyR)
Complete (Confirmed3) [95% CI]
(potrjen3) [95 % interval zaupanja]
Complete (Confirmed3) [95% CI]
(potrjen3) [95 %interval zaupanja] delen
Complete (Confirmed3) [95% CI]
popoln (potrjen3) [95 %-ni
Complete a partial injection (only when needed).
Dokončajte z delnim injiciranjem (le po potrebi).
Complete alopecia related/possibly related to topotecan administration was observed in 9 % of patients and partial alopecia related/possibly related to topotecan administration in 11 % of patients.
Popolno alopecijo, povezano ali morda povezano z uporabo topotekana, so zabeležili pri 9 % bolnikov, delno takšno alopecijo pa pri 11 %.
Complete and consistent blocking of the interleukin-2 receptor is maintained as long as serum basiliximab levels exceed 0.2 g/ml (usually up to 4–6 weeks after administration).
Popolna in dosledna zavora receptorja za interlevkin 2 traja, dokler serumska koncentracija baziliksimaba presega 0,2 g/ml (običajno do
Complete asparagine depletion in CSF
Popolno izčrpanje asparagina v CSF
Complete asparagine depletion in serum
Popolno izčrpanje asparagina v serumu
Complete baseline tests and screening as decribed in SmPC section 4.
Opravite vse preiskave in presejanja v izhodišču, kot so opisana v poglavju 4 povzetka glavnih značilnosti zdravila.
Complete blood and platelet counts should be obtained at regular intervals, more frequently in patients who develop cytopaenias.
V rednih intervalih je treba opraviti pregled celotne krvne slike in štetje trombocitov, pogosteje pri bolnikih, pri katerih se pojavi citopenija.
Complete blood cell count monitoring is recommended during ONIVYDE treatment.
Med zdravljenjem z zdravilom ONIVYDE se priporoča nadziranje celotne krvne slike.
Complete blood cell counts must be obtained prior to initiation of therapy and as needed to monitor toxicity, but at a minimum, prior to each treatment cycle.
Pred uvedbo zdravljenja in z namenom spremljanja toksičnosti zdravila, najmanj pred vsakim ciklom zdravljenja, je treba pregledati celotno krvno sliko.
Complete blood cell counts should be performed as clinically indicated.
Opraviti je treba pregled celotne krvne slike, kot je klinično indicirano.
Complete blood count results (see above under ITP) should be used to monitor for cytopenias.
Za spremljanje citopenije naj se uporabljajo rezultati celotne krvne slike (glejte razdelek o ITP).
Complete blood count with differential (prior to treatment initiation and at monthly intervals thereafter)
Celotna in diferencialna krvna slika (pred uvedbo zdravljenja in nato v mesečnih presledkih)
Complete blood counts (with white blood cell differential counts) should be obtained at pretreatment, and at Treatment
Preiskavo popolne krvne slike (z diferencialno sliko belih krvnih celic) je treba opraviti pred zdravljenjem in 2., 4., 8. ter
Complete blood counts (with white blood cell differential counts) should be obtained at pretreatment, and at Treatment Weeks 2, 4, 8, 12, and should be monitored closely at other time points, as clinically appropriate.
Preiskavo popolne krvne slike (z diferencialno sliko belih krvnih celic) je treba opraviti pred zdravljenjem in 2., 4., 8. ter 12. teden zdravljenja in jo skrbno spremljati, ko je klinično primerno.
Complete blood counts (with white blood cell differential counts) should be obtained at pretreatment, and at Treatment Weeks 2, 4, 8, and 12, and should be monitored closely at other time points, as clinically appropriate.
Celotno krvno sliko (z diferencialno sliko belih krvnih celic) je treba pregledati pred začetkom zdravljenja, v 2., 4., 8. in 12. tednu zdravljenja in jo skrbno spremljati v drugih časovnih obdobjih, kot je klinično primerno.
Complete blood counts (with white blood cell differential counts) should be obtained at pretreatment, and at Treatment Weeks 2, 4, 8, and 12, and should be monitored closely at other time points, as clinically appropriate.
Preiskavo popolne krvne slike (z diferencialno sliko belih krvnih celic) je treba opraviti pred zdravljenjem in 2., 4., 8. ter 12. teden zdravljenja in jo skrbno spremljati, ko je klinično primerno.
Complete blood counts including platelets must be monitored regularly (see sections 4.4 and 4.8).
Redno je treba spremljati celotno krvno sliko, vključno s številom trombocitov (glejte poglavji 4.4 in 4.8).
Complete blood counts should be performed at the beginning of each treatment cycle for patients receiving treatment with sunitinib.
Bolnikom, zdravljenim s sunitinibom, je treba na začetku vsakega ciklusa zdravljenja pregledati celotno krvno sliko.
Complete blood counts with differential should be obtained prior to initiation of treatment and at monthly intervals thereafter until 48 months after the last infusion.
Pred uvedbo zdravljenja in nato v mesečnih presledkih do 48 mesecev po zadnjem infundiranju je treba določati celotno in diferencialno krvno sliko.
Complete blood counts, including neutrophil and platelet counts should be obtained at regular intervals during ofatumumab therapy and more frequently in patients who develop cytopenias.
Med zdravljenjem z ofatumumabom je treba redno kontrolirati celotno krvno sliko, vključno s številom nevtrofilcev in trombocitov; pri bolnikih, ki se jim pojavijo citopenije, morajo biti takšne kontrole pogostejše.
Complete Control (Complete Response and No More Than Mild Nausea) p-value c
Popolna kontrola (popoln odgovor in le blaga slabost) p-  c
Complete Control (Complete Response and No More Than Mild Nausea) p-valuec
Popolna kontrola (popoln odziv in kvečjemu blaga navzea) vrednost pc
Complete crossresistance was noted between indinavir and ritonavir; however, crossresistance to saquinavir varied among isolates.
Popolno navzkrižno rezistenco so ugotovili med indinavirjem in ritonavirjem; stopnja navzkrižne rezistence s sakvinavirom pa se je med izolati spreminjala.
Complete CyR n (%)
bolniki s popolnim citogenetičnim odzivom, število (%)
Complete fistula response (%) b
Popoln odziv fistule (%) b
Complete fistula response (%)b
Popoln odziv fistule (%) b
Complete haematologic response (CHR) for AP and BP CML: WBC less than or equal to institutional ULN, platelets greater than or equal to 100,000/mm3 and less than 450,000/mm3, absolute neutrophil count (ANC) greater than or equal to 1.0×109/L, no blasts or promyelocytes in peripheral blood, less than 5% myelocytes + metamyelocytes in bone marrow, less than 20% basophils in peripheral blood, and no extramedullary involvement.
Popolni hematološki odziv (CHR) za KML v pospešeni in blastni fazi: število belih krvnih celic manjše od ali enako zgornji meji normale (ZMN), število trombocitov večje od ali enako 100.000/mm3 in manjše od 450.000/mm3, absolutno število nevtrofilcev (ANC) večje od ali enako 1,0 x 109/l, odsotnost blastocitov ali promielocitov v periferni krvi, manj kot 5 % mielocitov + metamielocitov v kostnem mozgu, manj kot 20 % bazofilcev v periferni krvi in odsotnost ekstramedularnih dejavnikov.
Complete haematological
popolni hematološki
Complete haematological response (CHR)
popolni hematološki odziv (CHR)
complete haematological responses and no evidence of leukaemia. b CHR: WBC ≤ institutional ULN, ANC ≥1000/mm3, platelets ≥100,000/mm3, no blasts or promyelocytes in peripheral blood, bone marrow blasts ≤5%, <5% myelocytes plus metamyelocytes in peripheral blood, basophils <5% in peripheral blood, No extramedullary involvement (including no hepatomegaly or splenomegaly). c MCyR combines both complete (No detectable Ph+ cells) and partial (1% to 35% Ph+ cells) cytogenetic responses.
promielocitov v periferni krvi, blasti kostnega mozga ≤ 5 %, < 5 % mielociti plus metamielociti v periferni krvi, bazofilci < 5 % v periferni krvi, brez ekstramedularne vpletenosti (vključno brez hepatomegalije ali splenomegalije). c MCyR združuje celovite (brez zaznavnih celic Ph+) in delne (1 % do 35 % celic Ph+) citogenetske odgovore.
Complete Hematologic Normalization, n (%)
popolna hematološka normalizacija, n (%)
Complete recovery was seen after treatment discontinuation:
Po prekinitvi zdravljenja so bolniki popolnoma okrevali:
Complete Remission
popolna remisija
Complete remission (CR) was defined as the absence of visible leukaemic cells in the bone marrow and peripheral recovery of platelets and white blood cells.
Popolna remisija (CR – »complete remission«) je bila opredeljena kot odsotnost vidnih levkemičnih celic v kostnem mozgu ter periferalna obnovitev krvnih ploščic in belih krvnih celic.
Complete remission (CR)1/Complete remission with partial haematological recovery (CRh*)2
Popolna remisija (CR)1/popolna remisija z delnim hematološkim okrevanjem (CRh*)2
Complete remission rate at end of induction treatment
Celotna pogostnost remisije na koncu indukcijskega zdravljenja
Complete resolution
Popolno izginotje
Complete resolution of constitutional symptomsb
Popolno izginotje konstitutivnih simptomovb
Complete Responders (%)
Bolniki s popolnim odzivom (%)
Complete response
Popolni odgovor
Complete Response
Popolni odziv
Complete response %
Popolni odgovor
Complete response (%)a
Popolni odziv (%)a
Complete response (0-24 hours) †
Popoln odziv (0-24 ur)
Complete response (CR) [n]
popolni odziv (CR) [n]
Complete response (CR) Partial Response (PR) Stable disease (SD) Progressive disease (PD)
Delni odgovor (PR) Stabilna bolezen (SD) Napredovanje bolezni (PD)
Complete response (CR) was evaluated at the end of Block 1.
Popolni odgovor (CR – Complete Response) so ocenili na koncu 1. sklopa zdravljenja.
Complete response (CR), partial response (PR) and overall response (CR+PR) rates in the lenalidomide/dexamethasone arm remain significantly higher than in the dexamethasone/placebo arm in both studies.
Pogostnost popolnega odziva (CR – complete response), delnega odziva (PR – partial response) in celokupnega odziva (CR+PR) je bila še naprej v skupini, ki je prejemala lenalidomid/deksametazon, v obeh študijah pomembno večja kot v skupini, ki je prejemala placebo/deksametazon.
Complete Response (CR/CRu) rate*
Delež popolnega odgovora (CR/CRu)
Complete Response (No Emesis and No Rescue Medication) 97.5 % CI b
Popoln odgovor (brez bruhanja in dodatnega zdravljenja) 97,5 % CIb
Complete Response (No Emesis and No Rescue Medication) 98.3 % CIb
Popoln odziv (brez bruhanja in dodatnega zdravila) 98,3-odstotni interval zaupanjab
Complete response (no emesis and no rescue therapy)
Popoln odziv (brez bruhanja in brez rešilnega zdravljenja)
Complete response [n, %]
Celokupni odziv Popolni odziv [n, %]
Complete response [n, %]
Popolni odziv [n, %]
Complete response and overall response rates in the lenalidomide/dexamethasone arm were also significantly higher than the dexamethasone/placebo arm in both studies.
Pogostnost popolnega odziva in celokupnega odziva je bila v skupini, ki je prejemala lenalidomid/deksametazon, v obeh študijah pomembno večja kot v skupini, ki je prejemala placebo/deksametazon.
Complete Response by Day+100
Popoln odziv do 100.+ dneva
Complete response rate point estimates were 33.0% (95% CI: 23.3; 43.8) and 26.1% (95% CI: 17.3; 36.6) in the MabThera intravenous and subcutaneous arms, respectively.
Ocenjeni delež popolnega odgovora je bil 33,0 % (95-% IZ: 23,3; 43,8) v skupini z intravensko obliko zdravila MabThera in 26,1 % (95-% IZ: 17,3; 36,6) v skupini s podkožno obliko zdravila Mabthera.
Complete response* – Acute phase
Popoln odziv* – akutna faza
Complete response* – Delayed phase
Popoln odziv* – zapoznela faza
Complete response* – Overall phase
Popoln odziv* – celotna faza
Complete responses
popolni odzivi
Complete response†
Popoln odziv
Complete response‡
Popoln odziv
Complete resuspension is indicated by a uniformly opaque white suspension and absence of any material on stopper and vial surfaces.
Popolno resuspendiranje označuje enakomerno bela motna suspenzija in odsotnost kakršne koli snovi na površini zamaška in viale.
Complete the other stages of injection without delay.
Brez odlašanja opravite vse ostale korake za injiciranje.
Complete the other stages of injection without delay.
Vse ostale korake injiciranja opravite brez odlašanja.
Complete these steps before applying IONSYS to the patient:
Pred namestitvijo sistema IONSYS na bolnikovo kožo poskrbite za naslednje:
Complete TMA response
Popoln odgovor TMA
Complete weaning
Popolna ukinitev parenteralne prehrane
Completeb (CHR)
Celovitb (CHR)
Completed at least
Antihistaminik3
Completed at least 100 days of study drug prophylaxis
Zaključenih vsaj 100 dni profilakse s preiskovanim
Completed patients
Bolniki, ki so zdravljenje zaključili
Completed suicide Suicide attempt Pathological gambling Nervousness Aggression
poskus samomora patološko hazardiranje zivčnost agresija
Completed suicide, personality disorder, thinking abnormal
amomor), osebnostne motnje, motnje mišljenja
Completed suicide, personality disorder, thinking abnormal
samomor, osebnostne motnje, motnje mišljenja
Completely take off the film lid.
Zaščitno folijo odstranite v celoti.
Completely unscrew the injection needle assembly using an anti-clockwise turning motion as shown in Diagram R. Then carefully lift it off the pen and discard the capped injection needle (see Diagram S).
Do konca odvijte injekcijsko iglo s pokrovčkom, nasprotno smeri urnega kazalca, kot je prikazano na sliki R. Potem jo previdno dvignite s peresnika in zavrzite pokrito (glejte sliko S).
Completing 1 years
Dopolnjeno 1 leto
Completing 2 years
Dopolnjeni 2 leti
Complex behaviours such as “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported in patients taking sedative- hypnotics.
Pri bolnikih, ki jemljejo sedative/hipnotike, poročajo o oblikah kompleksnega vedenja, kakršna je “vožnja v polsnu” (tj., upravljanje motornega vozila v ne povsem budnem stanju po zaužitju sedativa-hipnotika in s poznejšo amnezijo za ta dogodek).
Complex behaviours such as “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported in patients taking sedative- hypnotics.
Pri bolnikih, ki jemljejo sedative/hipnotike, poročajo o oblikah kompleksnega vedenja, kakršna je “vožnja v polsnu” (tj., upravljanje motornega vozila v ne povsem budnem stanju po zaužitju sedativa/hipnotika in s poznejšo amnezijo za ta dogodek).
Complex of reactions due to the release of mediators of inflammation
kompleksna reakcija zaradi sproščanja mediatorjev vnetja,
Complex regional pain syndrome
indrom sestavljene regionalne
Compliance according to anti-HBs serum levels could be shown for 57 (of 61) patients (93%), with no values below 100 IU/l and a mean anti-HBs serum level of 254.3 IU/l at the final visit.
V skladu z ravnjo anti-HBs v serumu so sodelovanje prikazali za 57 (od 61) bolnikov (93 %), brez vrednosti pod 100 i.e./l in povprečnimi ravnmi anti-HBs v serumu 254,3 i.e/l ob končnem obisku.
Compliance level
Stopnja skladnosti
complicated (difficult to treat) infections of the tissues and organs within the belly (intra-abdominal infections);
zapletenih (težko ozdravljivih) okužb tkiv in organov v trebušnem predelu (intraabdominalnih okužb);
complicated (difficult to treat) infections of the urinary tract (structures that carry urine), including pyelonephritis (kidney infection);
zapletenih (težko ozdravljivih) okužb sečil (struktur za odvajanje urina), vključno s pielonefritisom (okužbo ledvic);
complicated eye surgery
zapleten kirurški poseg na očesu,
Complicated IAI2, 3
Zapletene IAI2, 3
Complicated infection in the abdomen
zapleteno okužbo v trebuhu
Complicated infection of the skin and soft tissues (the tissue below the skin), excluding diabetic foot infections.
zapleteno okužbo kože in mehkih tkiv (tkiva pod kožo), razen okužb diabetičnega stopala
complicated infections of the urinary tract (the structures that carry urine).
zapletene okužbe sečil (organov, ki prenašajo urin).
Complicated intra-abdominal infection*
Zapletene okužbe v trebušni votlini
Complicated intra-abdominal infections
Zapletene okužbe v trebušni votlini
Complicated intra-abdominal infections (see section 4.4);
zapletenih okužb v trebušni votlini (glejte poglavje 4.4),
Complicated skin and soft tissue (tissue below the skin) infections. ‘Complicated’ means that the infection is difficult to treat.
zapletenih okužb kože in mehkih (podkožnih) tkiv.
Complicated urinary tract infections
zapletene intraabdominalne okužbe, zapletene okužbe sečil
Complicated urinary tract infections
Zapletene okužbe sečil
Complicated Urinary Tract Infections, including pyelonephritis
Zapletene okužbe sečil, vključno s pielonefritisom
Complicated urinary-tract infections
Zapletene okužbe sečil
Complicated UTI,
Zapletene okužbe
Complication of severe OHSS
zaplet resnega OHSS
complications
edemi
Complications caused by cancer treatment due to break-down of cancer cells.
zapleti zaradi zdravljenja raka pri razkroju rakavih celic
Complications due to the underlying pancreatic cancer, especially biliary obstruction or presence of biliary stent, were identified as significant contributing factors.
Zapleta zaradi osnovne bolezni, to je rak trebušne slinavke, ki so ju prepoznali kot pomembna dejavnika, ki prispevata k nastanku sepse, sta zlasti biliarna obstrukcija ali prisotnost biliarnega stenta.
Complications during your procedure such as changes in heart rate, coughing or moving
Zapleti med posegom, kot so spremembe srčnega utripa, kašljanje ali premikanje.
complications in wound healing fluid retention/swelling in the body
zapleti pri celjenju ran zastajanje tekočine/otekanje v telesu
complications occurring after cancer treatment leading to increased blood levels of potassium, uric acid, and phosphate and decreased blood levels of calcium (tumour lysis syndrome)
zapleti, ki se pojavijo po zdravljenju raka in povzročijo zvišano koncentracija kalija, sečne kisline in fosfata v krvi ter znižano koncentracijo kalcija v krvi (sindrom lize tumorja),
complications of gall stones such as colic because of stones in bile duct, infection of the bile ducts or gall bladder
zapleti zaradi žolčnih kamnov, kot je kolika zaradi kamnov v žolčevodu, okužba žolčevoda ali žolčnika,
Complications of OHSS such as twisting of ovaries or blood clotting may occur rarely (may affect up to 1 in 1,000 people).
Zapleti OHSS, kot je torzija jajčnikov ali nastajanje krvnih strdkov, se pojavijo redko (prizadenejo lahko največ 1 od 1.000 bolnic).
Complications of OHSS such as twisting of ovaries or blood clotting may occur rarely (may affect up to 1 in 1000 people).
Zapleti OHSS, kot je zasuk (torzija) jajčnikov ali nastajanje krvnih strdkov, se pojavijo redko (pojavijo se lahko pri največ 1 bolniku od 1 000).
Complications of OHSS such as twisting of ovaries or blood clotting occur rarely (may affect up to 1 in 1,000 people).
Zapleti OHSS, kot je torzija jajčnikov ali nastajanje krvnih strdkov, se pojavijo redko (pojavijo se lahko pri do 1 od 1.000 bolnic).
Complications with skin healing after operations
zapleti s celjenjem ran po operaciji
Component
Sestavine
Component 1: 1 vial containing 1 ml of human clottable protein (50 – 90 mg/ml)
Raztopina 1: 1 viala vsebuje 1 ml humane koagulacijske beljakovine (50–90 mg/ml)
Component 1: 1 vial containing 2 ml human clottable protein (50 – 90 mg/ml) Component 2: 1 vial containing 2 ml of human thrombin (800 – 1200 IU/ml).
Raztopina 1: 1 viala vsebuje 2 ml humane koagulacijske beljakovine (50–90 mg/ml) Raztopina 2: 1 viala vsebuje 2 ml humanega trombina (800–1200 i.e./ml).
Component 1: 1 vial containing 2 ml of human clottable protein (50 – 90 mg/ml) Component 2: 1 vial containing 2 ml of human thrombin (800 – 1200 IU/ml).
Raztopina 1: 1 viala vsebuje 2 ml humane koagulacijske beljakovine (50–90 mg/ml) Raztopina 2: 1 viala vsebuje 2 ml humanega trombina (800–1200 i.e./ml).
Component 1: 1 vial containing 5 ml of human clottable protein (50 – 90 mg/ml) Component 2: 1 vial containing 5 ml of human thrombin (800 – 1200 IU/ml).
Raztopina 1: 1 viala vsebuje 5 ml humane koagulacijske beljakovine (50–90 mg/ml) Raztopina 2: 1 viala vsebuje 5 ml humanega trombina (800–1200 i.e./ml).
Component 1: Human clottable protein 50 – 90 mg/ml
Raztopina 1: humana koagulacijska beljakovina 50–90 mg/ml
Component 2: 1 vial containing 1 ml of human thrombin (800 – 1200 IU/ml).
Raztopina 2: 1 viala vsebuje 1 ml humanega trombina (800–1200 i.e./ml).
Component 2: Human thrombin 800-1200 IU/ml
Raztopina 2: humani trombin 800–1200 i.e./ml
Component of a 28 day pack, can’t be sold separately.
Sestavni del 28-dnevnega pakiranja, ni za posamično prodajo.
Component of a multi-pack, can’t be sold separately.
Del multi pakiranja, ni za posamično prodajo.
Component of a multi-pack, can’t be sold separately.
Del skupnega pakiranja z več peresniki, ni za ločeno prodajo.
Component of a multipack comprising 10 packs, each containing 1 bottle with 50 ml oral solution.
Sestavni del večkratnega pakiranja, ki sestoji iz 10 pakiranj, vsako pakiranje vsebuje 1 stekleničko s 50 ml peroralne raztopine.
Component of a multipack comprising 10 packs, each containing 14 tablets.
Del skupnega pakiranja, ki vsebuje 10 škatel po 14 tablet.
Component of a multipack comprising 10 packs, each containing 98 film-coated tablets.Not for separate sale.
Sestavni del večkratnega pakiranja, ki ga sestavlja 10 pakiranj, kjer vsako vsebuje 98 filmsko obloženih tablet.
Component of a multipack comprising 2 packs, each containing 5 pre-filled syringes
Skupno pakiranje po 2 pakiranji, od katerih vsako vsebuje 5 napolnjenih injekcijskih brizg
Component of a multipack comprising 2 packs, each containing 56 hard capsules.
Multipakiranje vsebuje 2 pakiranji in vsako vsebuje 56 trdih kapsul.
Component of a multipack comprising 2 packs, each containing 98 capsules.
Del večjega pakiranja, sestavljenega iz dveh pakiranj, ki vsebujeta po 98 kapsul.
Component of a multipack comprising 20 packs, each containing 42 film-coated tablets.
Sestavni del večkratnega pakiranja, ki ga sestavlja 20 pakiraj, od katerih vsako vsebuje 42 filmsko obloženih tablet.
Component of a multipack comprising 20 packs, each containing 42 film-coated tablets.
Sestavni del večkratnega pakiranja, ki ga sestavlja 20 pakiranj, kjer vsako vsebuje 42 filmsko obloženih tablet.
Component of a multipack comprising 20 packs, each containing 42 film-coated tablets.
Sestavni del večkratnega pakiranja, ki ga sestavlja 20 pakiranj, od katerih vsako vsebuje 42 filmsko obloženih tablet.
Component of a multipack comprising 20 packs, each containing 50 film-coated tablets.
Sestavni del večkratnega pakiranja, ki ga sestavlja 20 pakiranj, kjer vsako vsebuje 50 filmsko obloženih tablet.
Component of a multipack comprising 3 cartons, each containing 28 hard capsules.
Del skupnega pakiranja s 3 škatlami, od katerih vsaka vsebuje 28 trdih kapsul.
Component of a multipack comprising 3 packs, each containing 28 tablets.
del skupnega pakiranja s 3 škatlami po 28 tablet.
Component of a multipack comprising 3 packs, each containing 4 pens and 4 pen needles.
Element skupnega pakiranja, ki vsebuje 3 pakiranja, vsako s 4 peresniki in 4 iglami za peresnike.
Component of a multipack comprising 4 cartons.
Del skupnega pakiranja, ki obsega 4 škatle.
Component of a multipack comprising 4 intermediate packs, each containing 1 vial.
Del skupnega pakiranja, ki obsega 4 vmesna pakiranja, od katerih vsako vsebuje po 1 vialo.